Entities / Company
Tango Therapeutics (United States).
company in Cambridge, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 24
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
Tango Therapeutics and Protagonist Therapeutics are companies that operate within the medical and genetics industry sector.Speculative1 report
-
Analysts set price targets for Tango Therapeutics stock on July 14, 2025.Some support1 report
-
Analysts revised earnings estimates positively for Tango Therapeutics, strengthening the upside view.Some support1 report
-
Both Tango Therapeutics and Salesforce are companies currently operating in growth phases.Some support1 report
-
Tango Therapeutics' revenue growth forecast is higher than the industry average.Some support1 report
-
Barbara Weber has been appointed President and CEO of Tango Therapeutics.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Connections
The 3 strongest of 24, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Barbara Weber Structural
Barbara Weber serves as the President and CEO of Tango Therapeutics.
-
Adam Crystal Structural
Adam Crystal holds the executive role of President of Research and Development at Tango Therapeutics.
-
Revolution Medicines (United States) Structural
Tango Therapeutics utilizes RAS(ON) inhibitors developed by Revolution Medicines in its clinical trials.
History
Events by the month they beganJune 2026
6 events- Tango Therapeutics and Protagonist Therapeutics are companies that operate within the medical and genetics industry sector.
- Analysts set price targets for Tango Therapeutics stock on July 14, 2025.
- Analysts revised earnings estimates positively for Tango Therapeutics, strengthening the upside view.
- Both Tango Therapeutics and Salesforce are companies currently operating in growth phases.
- Tango Therapeutics' revenue growth forecast is higher than the industry average.
- Barbara Weber has been appointed President and CEO of Tango Therapeutics.